The Board of Directors has approved a share repurchase programme of up to DKK 14 billion to be executed during a 12 month period beginning 1 February 2018. The total programme may be reduced in size, if significant product in-licensing or bolt-on acquisition opportunities arise during 2018. Novo Nordisk expects to implement the majority of the new share repurchase programme according to the Safe Harbour Regulation.
In March 2018, at the Annual General Meeting, the Board of Directors proposed a further reduction in the company’s B share capital, by cancelling 10,000,000 treasury shares. After the implementation of the share capital reduction, Novo Nordisk’s share capital will amount to DKK 490,000,000, divided into A share capital of DKK 107,487,200 and B share capital of DKK 382,512,800.
|Year||Stock split history||Ratio of B-shares to ADRs|
|2014||January 2, B shares 1:5. January 9, ADRs 1:5||1:1|
|2007||December 3, 2007, B-shares 1:2, ADRs 1:2||1:1|
|2001||April 4, 2001, B-shares 1:5, ADRs 1:2.5||1:1|
||January 2, 1997 B-shares 1:2